Johnson & Johnson and Pfizer present meaningfully different leverage profiles, with Pfizer carrying substantially more gross debt relative to equity. For FY2025, JNJ's total debt sums to approximately $49.9B (long-term noncurrent $39.4B [JNJ:Q3] + current maturities $2.0B [JNJ:Q7] + short-term borrowings $8.5B [JNJ:Q11]) against stockholders' equity of $81.5B [JNJ:Q15], implying a debt-to-equity ratio of roughly 0.61x. PFE's FY2025 total debt stands at approximately $64.6B (long-term noncurrent $61.6B [PFE:Q3] + current maturities $3.0B [PFE:Q7]) against equity of $86.5B [PFE:Q15], a debt-to-equity ratio of roughly 0.75x. Pfizer's leverage surged dramatically after FY2022 — its long-term noncurrent debt nearly doubled from $32.9B [PFE:Q0] to $61.5B [PFE:Q1] in FY2023, reflecting the debt-financed acquisition of Seagen — and has remained elevated since. JNJ's debt load has also grown, with long-term noncurrent debt rising from $26.9B [JNJ:Q0] in FY2022 to $39.4B [JNJ:Q3] in FY2025, but the increase is more gradual. On a net-debt basis, JNJ's large cash balance ($19.7B [JNJ:Q19]) provides meaningful offset, whereas Pfizer holds far less cash ($1.1B [PFE:Q19]), leaving it with a substantially higher net debt burden.
JNJ: JNJ's leverage has risen over the past few years but remains manageable, with FY2025 total debt of roughly $49.9B (noncurrent $39.4B [JNJ:Q3], current maturities $2.0B [JNJ:Q7], short-term borrowings $8.5B [JNJ:Q11]) against equity of $81.5B [JNJ:Q15]. The company's substantial cash position of $19.7B [JNJ:Q19] meaningfully reduces net debt, supporting a relatively conservative balance sheet despite the uptick in borrowings.
PFE: Pfizer's leverage profile deteriorated sharply in FY2023 when long-term noncurrent debt nearly doubled to $61.5B [PFE:Q1] from $32.9B [PFE:Q0] in FY2022, driven by acquisition financing, and remained elevated at $61.6B [PFE:Q3] in FY2025. With only $1.1B in cash [PFE:Q19] and equity of $86.5B [PFE:Q15], Pfizer's net debt is substantial, making debt reduction a key balance-sheet priority in the near term.
Both JNJ and PFE are large-cap pharma companies, but the profitability evidence available here is uneven in depth. For JNJ, the fiscal first quarter of 2025 showed net earnings of $11.0 billion on a trailing basis with cash flow from operations of $4.2 billion [JNJ:S4], while interest income declined year-over-year in the nine-month period due to lower rates on cash balances even as interest expense rose on higher average debt [JNJ:S0]. For PFE, total revenues for the nine months ended September 28, 2025 were $45.0 billion, down from $45.9 billion in the prior-year period [PFE:S1], with cost of sales declining to $10.8 billion from $11.9 billion [PFE:S1], suggesting some gross margin improvement. Additionally, income from continuing operations before taxes rose $386 million to $3.2 billion in Q1 2026 versus $2.8 billion in Q1 2025, driven by higher revenues [PFE:S0]. Overall, JNJ's evidence points to solid earnings generation, while PFE shows modest top-line pressure but improving pre-tax income on a more recent basis.
JNJ: JNJ demonstrated solid earnings generation, with net earnings of approximately $11.0 billion and operating cash flow of $4.2 billion in the fiscal first quarter of 2025 [JNJ:S4]. However, interest income declined in the nine-month 2025 period relative to 2024 due to lower rates on cash balances, while interest expense increased on a higher average debt balance [JNJ:S0], creating a modest headwind to net profitability at the margin.
PFE: PFE faced modest top-line pressure, with nine-month 2025 total revenues of $45.0 billion compared to $45.9 billion in the prior-year period [PFE:S1], though cost of sales fell from $11.9 billion to $10.8 billion over the same stretch [PFE:S1], indicating some gross margin improvement. On a more recent basis, pre-tax income from continuing operations rose $386 million to $3.2 billion in Q1 2026 versus Q1 2025, supported by higher revenues [PFE:S0], suggesting a gradual profitability recovery is underway.
Across both axes, JNJ presents the stronger financial profile. Its leverage is more conservative — a lower debt-to-equity ratio and a large cash cushion that meaningfully offsets gross debt — and its earnings generation appears more robust, with solid net income and operating cash flow. Pfizer, by contrast, carries a heavier debt load accumulated through acquisition financing, a thin cash buffer that limits balance-sheet flexibility, and a top line that has faced modest pressure, even as early signs of margin improvement and pre-tax income recovery begin to emerge. For investors, JNJ's balance sheet and profitability stability contrast with Pfizer's higher-leverage, recovery-oriented positioning.
No claims flagged.